$129.46
0.00%
Nasdaq, Wed, Aug 13 2025
ISIN
US09627Y1091
Symbol
BPMC

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$576.2m
Shares outstanding
64.6m
Valuation (TTM | estimate)
P/E
- | -
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
25.3%
Return on Equity
-22.5%
ROCE
-18.4%
ROIC
-32.2%
Debt/Equity
1.1
Financials (TTM | estimate)
Revenue
$562.1m | $735.0m
EBITDA
$-158.4m | $-83.1m
EBIT
$-174.3m | $-79.6m
Net Income
$-155.7m | $-58.6m
Free Cash Flow
$-150.9m
Growth (TTM | estimate)
Revenue
99.1% | 44.5%
EBITDA
63.0% | 57.5%
EBIT
60.5% | 62.5%
Net Income
46.0% | 12.7%
Free Cash Flow
64.9%
Margin (TTM | estimate)
Gross
96.5%
EBITDA
-28.2% | -11.3%
EBIT
-31.0%
Net
-27.7% | -8.0%
Free Cash Flow
-26.9%
More
EPS
$-2.3
FCF per Share
$-2.3
Short interest
5.5%
Employees
649
Rev per Employee
$780.0k
Show more

Is Blueprint Medicines Corp. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

Blueprint Medicines Corp. Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Blueprint Medicines Corp. forecast:

7x Buy
28%
18x Hold
72%

Analyst Opinions

25 Analysts have issued a Blueprint Medicines Corp. forecast:

Buy
28%
Hold
72%

Financial data from Blueprint Medicines Corp.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
562 562
99% 99%
100%
- Direct Costs 20 20
131% 131%
4%
542 542
98% 98%
96%
- Selling and Administrative Expenses 372 372
22% 22%
66%
- Research and Development Expense 345 345
15% 15%
61%
-158 -158
63% 63%
-28%
- Depreciation and Amortization 16 16
25% 25%
3%
EBIT (Operating Income) EBIT -174 -174
60% 60%
-31%
Net Profit -156 -156
46% 46%
-28%

In millions USD.

Don't miss a Thing! We will send you all news about Blueprint Medicines Corp. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Blueprint Medicines Corp. Stock News

Neutral
Business Wire
14 days ago
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Blueprint (Nasdaq: BPMC) and its transaction with Sanofi. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Blueprint insiders received substantial benefits as part of change of c...
Neutral
Business Wire
3 months ago
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Blueprint Medicines Corporation (NasdaqGS: BPMC) to Sanofi (NasdaqGS: SNY). Under the terms of the proposed transaction, shareholders of Blueprint will receive $129.00 per share in cash at closing, and ...
Neutral
PRNewsWire
3 months ago
-- Breadth of presentations, including one oral and two flash talks, showcase Blueprint Medicines' leadership role in advancing care for patients with systemic mastocytosis -- CAMBRIDGE, Mass. , June 12, 2025 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced data presentations reflecting over a decade of collaboration with clinical experts and patient advocates to t...
More Blueprint Medicines Corp. News

Company Profile

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Head office United States
CEO Kathryn Haviland
Employees 649
Founded 2008
Website www.blueprintmedicines.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today